Dexamethasone should not be given to people with a chronic subdural haematomaBMJ 2022; 377 doi: https://doi.org/10.1136/bmj.o1302 (Published 10 June 2022) Cite this as: BMJ 2022;377:o1302
- Helen Saul, editor in chief1,
- Deniz Gursul, research dissemination manager1,
- Samantha Cassidy, science writer1,
- Peter Hutchinson, professor of neurosurgery2,
- Angelos Kolias, consultant neurosurgeon and clinical senior lecturer2
- 1NIHR Centre for Engagement and Dissemination, Twickenham, UK
- 2Addenbrooke’s Hospital and University of Cambridge, UK
- Correspondence to H Saul
Hutchinson P, Edlmann E, Bulters D, et al. Trial of dexamethasone for chronic subdural haematoma. N Engl J Med 2020;383:2616-27.
To read the full NIHR Alert, go to: https://evidence.nihr.ac.uk/alert/dexamethasone-should-not-be-used-chronic-subdural-haematoma/
Competing interests: The BMJ has judged that there are no disqualifying financial ties to commercial companies. The authors declare the following other interests: none.
Further details of The BMJ policy on financial interests are here: https://www.bmj.com/about-bmj/resources-authors/forms-policies-and-checklists/declaration-competing-interests.
All authors contributed to the development and review of this summary, as part of the wider NIHR Alerts editorial team.
More summaries of NIHR research are available at https://evidence.nihr.ac.uk/alerts/.
Disclaimer: NIHR Alerts are owned by the Department of Health and Social Care and are made available to The BMJ under licence. NIHR Alerts report and comment on health and social care research but do not offer any endorsement of the research. The NIHR assumes no responsibility or liability arising from any error or omission or from the use of any information contained in NIHR Alerts.
Permission to reuse these articles should be directed to NIHRAlerts@nihr.ac.uk.